Atea Pharmaceuticals Inc. (AVIR)
| Bid | 2.66 |
| Market Cap | 225.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -168.38M |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | -1.33 |
| Forward PE | -1.96 |
| Analyst | Hold |
| Ask | 2.67 |
| Volume | 109,574 |
| Avg. Volume (20D) | 328,175 |
| Open | 2.70 |
| Previous Close | 2.69 |
| Day's Range | 2.63 - 2.73 |
| 52-Week Range | 2.60 - 4.14 |
| Beta | 0.17 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed ...
Analyst Forecast
According to 1 analyst ratings, the average rating for AVIR stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 125.14% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call TranscriptAtea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communicat...